Dimensional Fund Advisors
SPRY icon

Dimensional Fund Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Dimensional Fund Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$925K Sell
115,523
-56,816
-33% -$489K ﹤0.01% 2880
2026
Q1 		$1.38M Sell
172,339
-3,783
-2% -$36.3K ﹤0.01% 2779
2025
Q4 		$2.05M Sell
176,122
-2,026
-1% -$19.7K ﹤0.01% 2734
2025
Q3 		$1.79M Sell
178,148
-2,344
-1% -$33.6K ﹤0.01% 2787
2025
Q2 		$3.15M Sell
180,492
-7,153
-4% -$103K ﹤0.01% 2639
2025
Q1 		$2.36M Sell
187,645
-8,813
-4% -$106K ﹤0.01% 2687
2024
Q4 		$2.07M Buy
196,458
+4,010
+2% +$56.2K ﹤0.01% 2777
2024
Q3 		$2.79M Hold
192,448
– – ﹤0.01% 2701
2024
Q2 		$1.64M Sell
192,448
-82,841
-30% -$735K ﹤0.01% 2808
2024
Q1 		$2.81M Sell
275,289
-49,437
-15% -$369K ﹤0.01% 2708
2023
Q4 		$1.78M Sell
324,726
-49,012
-13% -$215K ﹤0.01% 2810
2023
Q3 		$1.41M Sell
373,738
-19,912
-5% -$131K ﹤0.01% 2851
2023
Q2 		$2.64M Buy
393,650
+59,391
+18% +$396K ﹤0.01% 2710
2023
Q1 		$2.18M Buy
+334,259
New +$2.57M ﹤0.01% 2728
2022
Q3 		$1.75M Buy
330,734
+266,613
+416% +$1.31M ﹤0.01% 2750
2022
Q2 		$272K Buy
+64,121
New +$224K ﹤0.01% 3199

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dimensional Fund Advisors's SPRY Position: Q2 2026 in Review

Dimensional Fund Advisors reduced its ARS Pharmaceuticals (SPRY) stake by 33% in Q2 2026, selling an estimated $489K and leaving 115,523 shares worth $925K. The position accounts for ﹤0.01% of the portfolio, ranked #2880.

Dimensional Fund Advisors first reported a position in SPRY in Q2 2022 and has held it in 16 quarters since. The position peaked at $3.15M in Q2 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Dimensional Fund Advisors held 115,523 shares of ARS Pharmaceuticals worth $925K as of Q2 2026.
  • Dimensional Fund Advisors sold 56,816 ARS Pharmaceuticals shares in Q2 2026, an estimated $489K.
  • ARS Pharmaceuticals made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2880 holding.
  • Dimensional Fund Advisors first reported a position in ARS Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • Dimensional Fund Advisors's ARS Pharmaceuticals position peaked at $3.15M in Q2 2025.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.